Agios Pharmaceuticals (AGIO) Projected to Post Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is expected to be posting its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect Agios Pharmaceuticals to post earnings of ($1.94) per share and revenue of $10.4890 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:00 AM ET.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.19). The business had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $9.46 million. Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. On average, analysts expect Agios Pharmaceuticals to post $-7 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Agios Pharmaceuticals Stock Down 3.9%

Shares of NASDAQ AGIO opened at $41.74 on Thursday. The stock has a market cap of $2.43 billion, a PE ratio of 3.79 and a beta of 0.83. Agios Pharmaceuticals has a 52-week low of $23.42 and a 52-week high of $62.58. The business has a 50-day moving average price of $38.78 and a 200 day moving average price of $34.88.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 3,651 shares of the stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $36.77, for a total transaction of $134,247.27. Following the completion of the sale, the chief financial officer directly owned 33,870 shares of the company’s stock, valued at approximately $1,245,399.90. This trade represents a 9.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Brian Goff sold 11,085 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $36.67, for a total value of $406,486.95. Following the transaction, the chief executive officer directly owned 123,528 shares of the company’s stock, valued at approximately $4,529,771.76. This trade represents a 8.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,482 shares of company stock valued at $864,025. 4.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Large investors have recently modified their holdings of the business. NewEdge Advisors LLC purchased a new position in shares of Agios Pharmaceuticals during the 1st quarter worth approximately $40,000. Acadian Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals during the 1st quarter worth approximately $133,000. Tower Research Capital LLC TRC raised its stake in shares of Agios Pharmaceuticals by 634.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,440 shares of the biopharmaceutical company’s stock worth $214,000 after buying an additional 5,563 shares in the last quarter. Norges Bank purchased a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $225,000. Finally, Cerity Partners LLC purchased a new position in Agios Pharmaceuticals in the 2nd quarter valued at approximately $226,000.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on AGIO. Scotiabank decreased their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a research report on Monday, July 28th. Zacks Research cut Agios Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, October 8th. Bank of America decreased their target price on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $56.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, September 4th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $57.25.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.